Celgene Corporation (CELG) Fundamentals

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
SHARE INFORMATION
Market Cap$ 77,035,975,315
Shares Outstanding711,714,480
Float701,349,068
Percent Float98.54%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 14,003,588,326
Latest Fiscal EPS$ 0.00
Latest Fiscal Date2018-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions2,430
Institutional Holdings Date2019-11-30
Institutional Bought Previous 3 Months57,800,919
Institutional Holdings Percent93.3%
Institutional Sold Previous 3 Months135,564,227
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned3,829,837
TRADING INFO
52 Week High$ 110.70
52 Week Low$ 82.26
52 Week High Change$ 23.59
21 Day Moving Average$ 108.24
21 Day Extended Moving Average$ 108.2027
50 Day Moving Average$ 108.2128
50 Day Extended Moving Average$ 107.0055
200 Day Moving Average$ 98.5972
200 Day Extended Moving Average$ 99.4349
10 Day Average Volume-
20 Day Average Volume-
30 Day Average Volume3,810
50 Day Average Volume2,653,282
Alpha-0.008964
Beta1.4552
Standard Deviation0.100701
R20.250881
7 Day Price Change$ 0.00
7 Day Percent Change0.0%
21 Day Price Change$ 0.00
21 Day Percent Change0.0%
30 Day Price Change$ 0.00
30 Day Percent Change0.0%
Month to Date Price Change$ 0.00
Month to Date Percent Change0.0%
Quarter to Date Price Change$ 0.00
Quarter to Date Percent Change0.0%
180 Day Price Change$ 14.96
180 Day Percent Change16.04%
200 Day Price Change$ 9.33
200 Day Percent Change9.43%
Year to Date Price Change$ 0.00
Year to Date Percent Change0.0%

Celgene Corporation (CELG) Key Ratios

PROFITABILITY
EBIT Margin43.8%
EBITDA Margin47.6%
Pre-Tax Profit Margin27.6%
Profit Margin Count34.89%
Gross Margin96.3%
Profit Margin TOT34.89%
INCOME STATEMENTS
Revenue$ 15,921,301,402
Revenue Per Share$ 22.3703
Revenue (3 Years)$ 14.26
Revenue (5 Years)$ 17.47
FINANCIAL STRENGTH
Price to Tangible Book-6.20
Total Debt To Equity1.60
Int Coverage9.70
Current Ratio2.90
Leverage Ratio4.20
Quick Ratio2.60
Long Term Debt To Capital0.60
VALUATION MEASURES
PE Ratio13.40
Enterprise Value$ 76,674,157,534
Price to Sales4.8385
Price to Free Cash11.20
PE High Last 5 Years101.80
Price To Book6.40
Price To Cash Flow9.60
PE Low Last 5 Years17.50
Price to Tangible Book-6.20
MANAGEMENT EFFECTIVENESS
Receivables Turnover7.90
Invoice Turnover0.90
Assets Turnover0.50
Return Assets16.01
Return on Equity70.65
Return on Capital22.26

Celgene Corporation (CELG) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorKPMG LLP
CEOMark J. Alles
Emplyoees8852
Last AuditUE
CIK0000816284
IndustryDrug Manufacturers
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address86 Morris Avenue
Summit, NJ 7901
Websitehttp://www.celgene.com
Facsimile-
Telephone+1 908 673-9000
Emailir@celgene.com


Your Recent History
NASDAQ
CELG
Celgene
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.